Literature DB >> 24712895

Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer.

Siao-Yi Wang1, Janet E Cowan1, K Clint Cary1, June M Chan1, Peter R Carroll1, Matthew R Cooperberg1.   

Abstract

OBJECTIVE: To assess the ability of current nomograms to predict disease progression at repeat biopsy or at delayed radical prostatectomy (RP) in a prospectively accrued cohort of patients managed by active surveillance (AS).
MATERIALS AND METHODS: A total of 273 patients meeting low-risk criteria who were managed by AS and who underwent multiple biopsies and/or delayed RP were included in the study. The Kattan (base, medium and full), Steyerberg, Nakanishi and Chun nomograms were used to calculate the likelihood of indolent disease ('nomogram probability') as well as to predict 'biopsy progression' by grade or volume, 'surgical progression' by grade or stage, or 'any progression' on repeat biopsy or surgery. We evaluated the associations between each nomogram probability and each progression outcome using logistic regression with (area under the receiver-operating characteristic curve (AUC) values and decision curve analysis.
RESULTS: The nomogram probabilities of indolent disease were lower in patients with biopsy progression (P < 0.01) and any progression on repeat biopsy or surgical pathology (P < 0.05). In regression analyses, nomograms showed a modest ability to predict biopsy progression, adjusted for total number of biopsies (AUC range 0.52-0.67) and any progression (AUC range 0.52-0.70). Decision curve analyses showed that all the nomograms, except for the Kattan base model, have similar value in predicting biopsy progression and any progression. Nomogram probabilities were not associated with surgical progression in a subgroup of 58 men who underwent delayed RP.
CONCLUSIONS: Existing nomograms have only modest accuracy in predicting the outcomes of patients undergoing AS. Improvements to existing nomograms should be made before they are implemented in clinical practice and used to select patients for AS.
© 2013 The Authors. BJU International © 2013 BJU International.

Entities:  

Keywords:  active surveillance; nomograms; prediction; progression; prostate cancer

Mesh:

Year:  2014        PMID: 24712895     DOI: 10.1111/bju.12554

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  23 in total

1.  A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.

Authors:  M L Blute; J M Shiau; M Truong; Fangfang Shi; E J Abel; T M Downs; D F Jarrard
Journal:  World J Urol       Date:  2016-09-15       Impact factor: 4.226

2.  Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer.

Authors:  L M Wong; D E Neal; A Finelli; S Davis; C Bonner; J Kapoor; J Trachtenberg; B Thomas; C M Hovens; A J Costello; N M Corcoran
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-02-10       Impact factor: 5.554

Review 3.  Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies.

Authors:  Jonathan H Wang; Tracy M Downs; E Jason Abel; Kyle A Richards; David F Jarrard
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

Review 4.  [Molecular biomarkers and prognostic factors for prostate cancer].

Authors:  A Kretschmer; Y Tolkach; J Ellinger; G Kristiansen
Journal:  Urologe A       Date:  2017-07       Impact factor: 0.639

5.  Management of prostate cancer: NYU Case of the Month, July 2017.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2017

6.  Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance?

Authors:  Prassannah Satasivam; Bing Ying Poon; Behfar Ehdaie; Andrew J Vickers; James A Eastham
Journal:  J Urol       Date:  2015-07-17       Impact factor: 7.450

7.  CCL2 promotes integrin-mediated adhesion of prostate cancer cells in vitro.

Authors:  Igor Tsaur; Jochen Rutz; Jasmina Makarević; Eva Juengel; Kilian M Gust; Hendrik Borgmann; David Schilling; Karen Nelson; Axel Haferkamp; Georg Bartsch; Roman A Blaheta
Journal:  World J Urol       Date:  2014-09-02       Impact factor: 4.226

Review 8.  Clinical Utility of Biomarkers in Localized Prostate Cancer.

Authors:  Michael S Leapman; Hao G Nguyen; Matthew R Cooperberg
Journal:  Curr Oncol Rep       Date:  2016-05       Impact factor: 5.075

9.  A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients.

Authors:  Sami-Ramzi Leyh-Bannurah; Paolo Dell'Oglio; Zhe Tian; Jonas Schiffmann; Shahrokh F Shariat; Nazareno Suardi; Montorsi Francesco; Briganti Alberto; Hans Heinzer; Hartwig Huland; Markus Graefen; Lars Budäus; Pierre I Karakiewicz
Journal:  World J Urol       Date:  2016-06-11       Impact factor: 4.226

10.  [Active surveillance for low-risk prostate cancer].

Authors:  Annika Herlemann; Christian G Stief
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.